Sign In
Home
About Us
Benefits
Pricing
Krixos Global Intel
Krixos
Contact Us
Breaking Cancer News A-Z
Health/Pharma Companies
Drugs, Treatments, Trials
Hot Topics
Clinical Trials - Latest News
Other Illnesses & Conditions
Latest Healthcare News
My Settings
Client Requests
Advanced Search
My Viewed Articles
All Cancer News
Acute Lymphoblastic Leukemia
Acute myeloid leukemia
Adenocarcinoma
Adenoid Cystic Carcinoma
Adrenocortical Carcinoma
Anal Cancer
Anaplastic Astrocytoma
Angiosarcoma
Astrocytoma
Basal-Cell Carcinoma
Bladder Cancer
Brain Cancer
Breast Cancer
Cancer Cachexia
Carcinoma
Cervical Cancer
Childhood Cancer
Cholangiocarcinoma
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Colorectal Adenocarcinoma
Colorectal Cancer
Craniopharyngioma
Endometrial Cancer
Ependymoma
Esophageal Cancer
Ewing's Sarcoma
Gallbladder Cancer
Germ Cell Tumors
Glioblastoma
Glioma
Hairy Cell Leukemia
Hepatocellular Carcinoma
Hodgkin Lymphoma
Kaposi's Sarcoma
Kidney & Renal Cancer
Laryngeal Cancer
Leukemia
Liver Cancer
Lung Adenocarcinoma
Lung Cancer
Lymphoma
Mantle Cell Lymphoma
MCRPC
Medulloblastoma
Melanoma
Meningioma
Mesothelioma
Metastatic Colon Cancer
Mouth Cancer
Multiple Myeloma
Myelodysplastic Syndrome
Myelofibrosis
Nasopharyngeal Carcinoma
Neuroblastoma
NMIBC
Non-Hodgkin Lymphoma
NSCLC
Oral Cancer
Oropharyngeal Cancer
Osteosarcoma
Ovarian Cancer
Pancreatic Adenocarcinoma
Pancreatic Cancer
Pancreatic Neuroendocrine Tumors
Penile Cancer
Pheochromocytoma
Prostate Cancer
Retinoblastoma
Rhabdomyosarcoma
Sarcoma
Sarcopenia
Skin Cancer
Small Cell Lung Cancer
Squamous Cell Carcinoma
Stomach (Gastric) Cancer
Synovial Sarcoma
Testicular Cancer
Thymic Carcinoma
Thymoma
Thyroid Cancer
Tongue Cancer
Uterine Cancer
Vulvar Cancer
Waldenstrom Macroglobulinemia
You need to login...
Enter your email:
Enter your password:
If you are not registered...
Subscribe to Krixos Health:
Sign Up Now:
Your email:
or call us on: +43 (0)1 27 63 015
or email:
subscribe@krixos.com
Most viewed
1.
ALKBH3-regulated m1A of ALDOA potentiates glycolysis and doxorubicin resistance of triple negative breast cancer cells
2.
A bibliometric analysis of liver cancer bone metastases: advances in mechanisms of occurrence and treatment options
3.
Angelini Ventures Co-leads CHF 79 Million (€84 Million) Series B Financing of NUCLIDIUM to Advance Clinical Development of its Copper-based Radiopharmaceutical Platform
4.
BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in "Eye-Bulging" Breast Cancer Patient
5.
Swiss BioTech platform NUCLIDIUM raises €84 million for the diagnosis and treatment of cancer
6.
Radiopharma's new wave: Nuclidium and Actithera raise the stakes
7.
ALKBH3-regulated m1A of ALDOA potentiates glycolysis and doxorubicin resistance of triple negative breast cancer cells
8.
ESCO2 inhibition induces cell cycle arrest and apoptosis in breast cancer via the P53-CDK1 axis and the BAX/Bcl2/caspase signaling cascade
9.
Baseline MRI habitat imaging for predicting treatment response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer
10.
Ultrasound-based radiomics combined with B3GALT4 level to predict sentinel lymph node metastasis in primary breast cancer
Last updated at 16:42 GMT
Hot News Makers
Health/Pharma Companies
WuXi PharmaTech
20070.96
WuXi AppTec
17203.68
WuXi Biologics
12805.75
Milestone Pharmaceuticals
11231.75
Samsung Biologics
9324.67
Visionable
8861.49
Chinese Academy of Sciences
6645.98
Capricor Therapeutics
5370.66
Humana
3381.65
Seer
2968.87
Drugs, Treatments, Trials
Fentanyl
54383.82
Alectinib
15216.33
Lidocaine
6272.95
Doxorubicin
1896.46
Cetuximab
1861.41
AgenT-797
1526.59
PanSeer
1282.34
Bevacizumab
1229.95
NUC-3373
1187.35
Nivolumab
1086.34
Last updated at 16:10 GMT